Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
A key Japanese health ministry panel on August 26 backed approval of Ono Pharmaceutical’s epilepsy drug cenobamate, known as Xcopri overseas, and a subcutaneous formulation of Eisai’s Alzheimer’s therapy Leqembi (lecanemab), along with other drugs and indications. The Pharmaceutical Affairs…
To read the full story
Related Article
- Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
- Eisai Files Subcutaneous Leqembi Autoinjector in Japan
December 1, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- EA Pharma Files to Add Dosage for 1-Year-Olds to Movicol
October 27, 2025
- Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan
October 14, 2025
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
REGULATORY
- Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
- Kisunla Braced for NHI Price Cut after CEA; Leqembi Method to Apply
August 27, 2026
- Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
August 27, 2026
- MHLW Lifts Olanzapine Diabetes Contraindication for Antiemetic Use
August 26, 2026
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…